A user is experiencing ongoing hair loss despite using 0.5mg dutasteride and 2.5mg oral minoxidil for several years and is seeking advice. Suggestions include ensuring correct diagnosis, checking for other health issues, considering finasteride, trying topical antiandrogens, and consulting a dermatologist.
This conversation discusses the potential benefits of using oral minoxidil and finasteride to treat hair loss, with some users sharing their own experiences in taking the medications. Others express concerns about the safety of these treatments.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.
People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.